Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 – The Daily Chronicle

TheAdipose Tissue-Derived Stem Cells (ADSCS) Marketresearch report thoroughly explains each and every aspect related to the Global Adipose Tissue-Derived Stem Cells (ADSCS) Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.

The Global Adipose Tissue-Derived Stem Cells (ADSCS) Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Adipose Tissue-Derived Stem Cells (ADSCS) market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Adipose Tissue-Derived Stem Cells (ADSCS) Market in each region. Various methodological tools are used to analyze the growth of the worldwide Adipose Tissue-Derived Stem Cells (ADSCS) market.

Adipose tissue-derived stem cells (ADSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account grow at a CAGR of 6.1% in the above-mentioned forecast period. The accelerating application of adipose tissue-derived stem cells (ADSCS) in the regenerative medicines research, development of cell linage, tissue engendering, bone and cartilage regeneration are driving the exponential growth of adipose tissue-derived stem cells (ADSCS) market during the forecast period of 2020 to 2027.

Get Free Sample PDF (including COVID19 Impact Analysis) of Adipose Tissue-Derived Stem Cells (ADSCS) Market[emailprotected] https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market&utm_source=&kA

Prominent Key Players Covered in the report:

Antria Inc., CELGENE CORPORATION, pluristem, Tissue Genesis, Cytori Therapeutics Inc., PRECIGEN, Mesoblast Ltd, CORESTEM, Inc, among other domestic and global players.

Major Regions as Follows:

A complete value chain of the global Adipose Tissue-Derived Stem Cells (ADSCS) market is presented in the research report. It is associated with the review of the downstream and upstream components of the Adipose Tissue-Derived Stem Cells (ADSCS) Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Adipose Tissue-Derived Stem Cells (ADSCS) market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Adipose Tissue-Derived Stem Cells (ADSCS) market.

The Objectives of the Adipose Tissue-Derived Stem Cells (ADSCS) Market Report:

How Does This Market Insights Help?

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market&utm_source=&KA

Market Dynamics:The Adipose Tissue-Derived Stem Cells (ADSCS) report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

Why choose us:

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Adipose Tissue-Derived Stem Cells (ADSCS) Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

COVID-19 Impact Analysis:

The report seeks to track the evolution of the market growth pathways and publish a medical crisis in an exclusive section publishing an analysis of the impact of COVID-19 on the Adipose Tissue-Derived Stem Cells (ADSCS) market. The new analysis on COVID-19 pandemic provides a clear assessment of the impact on the Adipose Tissue-Derived Stem Cells (ADSCS) market and the expected volatility of the market during the forecast period. Various factors that can affect the general dynamics of the Adipose Tissue-Derived Stem Cells (ADSCS) market during the forecast period (2020-2026), including current trends, growth opportunities, limiting factors, etc., are discussed in detail in this market research.

Else, Place an Enquiry Before Buying Adipose Tissue-Derived Stem Cells (ADSCS) Market: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market&utm_source=&KA

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Read more from the original source:
Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 - The Daily Chronicle

Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Latest Innovations and Forecast 2021-2026 : Qiagen, Advanced Cell…

The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market report comprises a valuable bunch of information that enlightens the most imperative sectors of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market. The data available in the report delivers comprehensive information about the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, which is understandable not only for an expert but also for a layman. The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report provides information regarding all the aspects associated with the market, which includes reviews of the final product, and the key factors influencing or hampering the market growth. Moreover, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report, particularly emphasizes on the key market players Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Creatv MicroTech, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, Aviva Biosciences Corporation, ScreenCell, Silicon Biosystems that are competing with each other to acquire the majority of share in the market, financial circumstances, actual certainties, and geographical analysis.

Click Here To Access The Sample Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report

For in-depth analysis and thorough understanding, the report presents a demand for individual segment in each region. It demonstrates various segmentsCellSearch, Otherand sub-segmentsBreast Cancer Diagnosis and Treatment, Prostate Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment, Lung Cancer Diagnosis and Treatment, Other Cancers Diagnosis and Treatmentof the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market. The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report explains in-depth about the quantitative as well as the qualitative scenario of the market. The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report delivers the precise analytical information that explains the future growth trend to be followed by the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, based on the past and current situation of the market.

In addition, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report delivers concise information about the federal regulations and policies that may indirectly affect market growth as well as the financial state. The situation of the global market at the global and regional level is also described in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report through geographical segmentation.

Read Detailed Index Of Full Research Study @::https://www.syndicatemarketresearch.com/market-analysis/circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market.html

The information available in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report is not only based on the facts but also on the case studies, which analysts have included to deliver appropriate information to the clients in a well-versed manner. Moreover, for better understanding, the report includes statistical figures, graphs, tables, and charts related to the information mentioned in textual form.

Chapter 1,Definition, Specifications and Classification of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) , Applications of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) , Market Segment by Regions; Chapter 2,Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3,Technical Data and Manufacturing Plants Analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4,Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5 and 6,Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Segment Market Analysis (by Type); Chapter 7 and 8,The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Segment Market Analysis (by Application) Major Manufacturers Analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) ; Chapter 9,Market Trend Analysis, Regional Market Trend, Market Trend by Product Type CellSearch, Other, Market Trend by Application Breast Cancer Diagnosis and Treatment, Prostate Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment, Lung Cancer Diagnosis and Treatment, Other Cancers Diagnosis and Treatment; Chapter 10,Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11,The Consumers Analysis of Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) ; Chapter 12,Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15,Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @:https://www.syndicatemarketresearch.com/inquiry/circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market

This report provides pin-point analysis for changing competitive dynamics It provides a forward looking perspective on different factors driving or restraining market growth It provides a six-year forecast assessed on the basis of how the market is predicted to grow It helps in understanding the key product segments and their future It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

At Syndicate Market Research, we provide reports about a range of industries such as healthcare & pharma, automotive, IT, insurance, security, packaging, electronics & semiconductors, medical devices, food & beverage, software & services, manufacturing & construction, defense aerospace, agriculture, consumer goods & retailing, and so on. Every aspect of the market is covered in the report along with its regional data. Syndicate Market Research committed to the requirements of our clients, offering tailored solutions best suitable for strategy development and execution to get substantial results. Above this, we will be available for our clients 247.

Syndicate Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Email ID:[emailprotected] Website:https://www.syndicatemarketresearch.com/ Blog:Syndicate Market Research Blog

Originally posted here:
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Latest Innovations and Forecast 2021-2026 : Qiagen, Advanced Cell...

Asia Pacific Tissue Engineering Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Material Type, Applications, and Country -…

October 01, 2020 17:56 ET | Source: ReportLinker

New York, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Material Type, Applications, and Country" - https://www.reportlinker.com/p05974344/?utm_source=GNW High cost associated to the tissue engineering process is one of the major factors restraining the growth of the market.

Additionally, increasing financial contributions by government and private sector are likely to fuel the growth of the APAC tissue engineering market during the forecast period. Tissue engineering is a blend of material methods and cellular activities.This approach involves the use of physicochemical and biochemical attributes of humans to replace the biological tissues and strengthen them.

It is an innovative technology that works either separately or in conjunction with scaffolds, stem cells, regenerative medicine, and growth factors or negotiators. The process utilizes molecular and cellular processes in combination with the principles of material engineering to surgically repair and restore tissue. The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period on the back of the increase in research activities, growing demand for organ transplants, rising number of initiatives by market players for expanding their presence in the region, and higher adoption of stem cell research in several APAC countries. China and India hold significant growth opportunities for players operating in the 3D bioprinting market, owing to the growing support from government bodies, increasing demand for cosmetic surgeries, and presence of less stringent regulations and data requirements than healthcare systems in developed countries. In July 2019, the Government of India collaborated with the US for the research and development of 3D bioprinting regenerative medicine.This collaboration involves the exchange of faculty members and students for the trade of scientific ideas/information and technologies, as well as the joint use of scientific infrastructure for research, especially in the field of 3D bioprinting.

The Government of South Korea announced plans to invest ~USD 37 million to boost the development of 3D bioprinting across the country. The countrys Ministry of Science announced plans to spend a considerable portion of its budget on a plethora of 3D bioprinting applications to strengthen its competitiveness and ability to meet demand. In APAC, due to an increasing number of COVID-19 infected patients, healthcare professionals and leading organizations are rechanneling the flow of healthcare resources from R&D to primary care, which is slowing down the process of innovation.Further, the COVID-19 pandemic is also hindering the conduct of clinical trials and drug development, and the operations of diagnostic industry in the region.

For instance, Stryker Corporation, a well-known player in the tissue engineering industry, has diverted operations to manufacture COVID-19 diagnostics and PPE kits.Moreover, according to a recent survey by Medscape in July 2020, substantial disruption has been witnessed in routine research activities that include tissue engineering and regenerative medicines as a result of the COVID-19 pandemic.

The rapid increase in the number of the infected patients in the India and China is likely to result in the slowdown of the market growth in the near future. In 2019, the biologically derived material segment accounted for the largest share of the APAC tissue engineering market.The growth of the market for this segment is attributed to the rising adoption of biomaterials due to their natural regenerative potential to restore tissue functioning and ability to facilitate the on demand release of chemokines with the procedure.

Further, the synthetic material segment is likely to register the highest CAGR in the market during the forecast period. A few of the significant secondary sources associated with the Asia Pacific tissue engineering market report are the World Health Organization (WHO), Government of India, Government of South Korea, and US Food and Drug Administration. Read the full report: https://www.reportlinker.com/p05974344/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Lyon, FRANCE

Formats available:

More:
Asia Pacific Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Material Type, Applications, and Country -...

Cell Separation Market 2020 Size Analysis by Growth Trends, Share, Opportunities and Business Strategy Forecast to 2024 – The Daily Chronicle

The Cell Separation market report explores exhaustive estimation of each vital aspect of the global Cell Separation industry that relates to market size, share, revenue, demand, sales volume, and development in the market. The Cell Separation market report provides key market segments along with sub-segments, market dynamics, and key players analysis. The research study also offers data on product types, market competitive scenario, recent trends, the growth rate of the industry.

About Cell Separation Market:

Cell Separation Market analysis considers sales from academic institutions and research laboratories, pharmaceutical and biotechnology companies, and hospitals and clinical testing laboratories end-users. Our study also finds the sales of cell separation in Asia, Europe, North America, and ROW. In 2019, the academic institutions and research laboratories segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as demand for cell separation to carry out research studies related to cell enumeration and cell functional assays will play a significant role in the academic institutions and research laboratories segment to maintain its market position. Also, our global cell separation market report looks at factors such as growing adoption of cell separation techniques in research and clinical applications, increasing use of cell separation in cancer research, and high prevalence of HIV/AIDS. However, presence of inconsistent reagents and other ancillary products, exposure risks faced by laboratory personnel, and risk of sample contamination may hamper the growth of the cell separation industry over the forecast period.

Get a Sample Copy of the Report https://www.industryresearch.co/enquiry/request-sample/14966977

Market Dynamics of Cell Separation Market:

Driver: Increasing Use Of Cell Separation In Cancer Research

Trends: Growing Focus On Personalized Medicine

Challenges: Presence Of Inconsistent Reagents

Increasing use of cell separation in cancer research

Cell separation helps the identification and characterization of cancer stem cells. The analysis of single cancer cells by medical practitioners can aid in the early diagnosis of tumors, the monitoring of circulating tumor cells, and the evaluation of intratumor heterogeneity. It can also aid the determination of the need for chemotherapeutic treatments. Also, the incidence of cancer is increasing rapidly, especially amongst women. Cervical and breast cancers are the most common types in the world. The rising incidence of cancer is encouraging further research in the field. Moreover, advances in computer techniques, optics, and lasers introduced a new generation of cell separation techniques which are capable of high speed processing of single cell suspensions. This use of cell separation in cancer research will lead to the expansion of the global cell separation market at a CAGR of over 17% during the forecast period.

Growing focus on personalized medicine

The high number of adverse drug reactions, rising awareness about early diagnosis, and advancements in genetic science are driving the growth of personalized medicines. Genome mapping studies are crucial for the development of personalized medicines, and they could only be achieved if cell separation is performed adequately in studies and research projects. The focus on analyzing DNA synthesis is increasing during cell separation, which can be used for the development of personalized medicines against targets. This development is expected to have a positive impact on the overall market growth.

Some Key Players of Cell Separation Market Are:

To Understand How Covid-19 Impact is Covered in This Report https://www.industryresearch.co/enquiry/request-covid19/14966977

Cell Separation Market Segmentation Analysis:

By Type:

Cell Separation Market Report Highlights:

Cell Separation Market Segment by Regions:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14966977

Some Points from Cell Separation Market Report TOC:

PART01:EXECUTIVESUMMARY

PART02:SCOPEOFTHEREPORT

PART03:MARKETLANDSCAPE

PART04:MARKETSIZING

PART05:FIVEFORCESANALYSIS

PART06:MARKETSEGMENTATIONBYTECHNOLOGY

PART07:MARKETSEGMENTATIONBYFURNACETYPE

PART08:CUSTOMERLANDSCAPE

PART09:GEOGRAPHICLANDSCAPE

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

Purchase this Report (Price 2500 USD for single user license) https://www.industryresearch.co/purchase/14966977

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

E Ink Market, Shellac Market, Global 3-Hexyn-2-Ol Market

Vehicle Tracking Systems Market, Commercial Aircraft Angle of Attack Sensors Market, Organic Acid Products Market

Solar PV Tracker Market, Global IoT Telecom Services Market, Vapor Pressure Osmometer Market

Nucleating And Clarifying Agents Market, Furniture Adhesives Market, Penicillin Active Pharmaceutical Ingredients Market

KN95 Medical Face Masks Market, WiFi Smart Garage Door Controllers Market, Convention Centers Design Market

, ,

Here is the original post:
Cell Separation Market 2020 Size Analysis by Growth Trends, Share, Opportunities and Business Strategy Forecast to 2024 - The Daily Chronicle

Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 Meeting – Business Wire

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces two presentations at the European Society for Immunodeficiencies (ESID) 2020 Meeting to be held virtually October 14-17, 2020. An oral presentation will provide an update on data from the Phase 1/2 clinical trial of RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I). An e-poster will highlight preclinical study data on RP-L401 for Infantile Malignant Osteopetrosis (IMO).

Additional presentation details can be found below:

Oral Presentation

Title: A Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Results from Phase 1 Session Title: Treatment Presenter: Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology, and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles Session Date: Friday, October 16, 2020 Session Time: 10:45 a.m. 12:01 p.m. CEST Lecture Time: 11:45 a.m. CEST Location: Hall D

This session will be followed by a Q&A from 12:01 p.m. to 12:30 p.m. CEST

E-Poster

Title: Preclinical Efficacy and Safety of EFS.HTCIRG1-LV Supports IMO Gene Therapy Clinical Trial Initiation Presenter: Ilana Moscatelli, Ph.D., Associate Researcher, Division of Molecular Medicine and Gene Therapy, Lund University, Sweden

About Leukocyte Adhesion Deficiency-I

Severe Leukocyte Adhesion Deficiency-I (LAD-I) is a rare, autosomal recessive pediatric disease caused by mutations in the ITGB2 gene encoding for the beta-2 integrin component CD18. CD18 is a key protein that facilitates leukocyte adhesion and extravasation from blood vessels to combat infections. As a result, children with severe LAD-I (less than 2% normal expression) are often affected immediately after birth. During infancy, they suffer from recurrent life-threatening bacterial and fungal infections that respond poorly to antibiotics and require frequent hospitalizations. Children who survive infancy experience recurrent severe infections including pneumonia, gingival ulcers, necrotic skin ulcers, and septicemia. Without a successful bone marrow transplant, mortality in patients with severe LAD-I is 60-75% prior to the age of 2 and survival beyond the age of 5 is uncommon. There is a high unmet medical need for patients with severe LAD-I.

Rockets LAD-I research is made possible by a grant from the California Institute for Regenerative Medicine (Grant Number CLIN2-11480). The contents of this press release are solely the responsibility of Rocket and do not necessarily represent the official views of CIRM or any other Agency of the State of California.

About Infantile Malignant Osteopetrosis

Infantile Malignant Osteopetrosis (IMO) is a rare, severe autosomal recessive disorder caused by mutations in the TCIRG1 gene, which is critical for the process of bone resorption. Mutations in TCIRG1 interfere with the function of osteoclasts, cells which are essential for normal bone remodeling and growth, leading to skeletal malformations, including fractures and cranial deformities which cause neurologic abnormalities including vision and hearing loss. Patients often have endocrine abnormalities and progressive, frequently fatal bone marrow failure. As a result, death is common within the first decade of life. IMO has an estimated incidence of 1 in 200,000. The only treatment option currently available for IMO is an allogenic bone marrow transplant (HSCT), which allows for the restoration of bone resorption by donor-derived osteoclasts which originate from hematopoietic cells. Long-term survival rates are lower in IMO than those associated with HSCT for many other non-malignant hematologic disorders; severe HSCT-related complications are frequent. There is an urgent need for additional treatment options.

RP-L401 was in-licensed from Lund University and Medizinische Hochschule Hannover.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The companys platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit http://www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon Disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rockets ongoing trials, our expectations regarding when clinical trial sites will resume normal business operations, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-Q for the quarter ended June 30, 2020, filed August 5, 2020 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Follow this link:
Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 Meeting - Business Wire